Rodrigo A Ledezma1, Edris Negron2, Aria A Razmaria2, Pankaj Dangle2, Scott E Eggener2, Arieh L Shalhav2, Gregory P Zagaja2. 1. Section of Urology, Department of Surgery, University of Chicago Medical Center, 5841 South Maryland Avenue, MC6038, J-664, Chicago, IL, 60637, USA. rodrigoledezma@gmail.com. 2. Section of Urology, Department of Surgery, University of Chicago Medical Center, 5841 South Maryland Avenue, MC6038, J-664, Chicago, IL, 60637, USA.
Abstract
PURPOSE: Limited data are available regarding the oncologic efficacy of pelvic lymph node dissection (PLND) performed during robotic-assisted laparoscopic prostatectomy (RALP) for prostate cancer. We aimed to determine the frequency of pelvic lymph node metastasis and oncological outcomes following RALP with PLND in patients who did not receive adjuvant androgen deprivation therapy (ADT). METHODS: We retrospectively reviewed the records of 1740 consecutive patients who underwent RALP and extended PLND. The primary endpoint was biochemical recurrence (BCR). The estimated BCR probability was obtained using the Kaplan-Meier method. Cox proportional hazard regression models were used to assess for predictors of BCR. RESULTS: One hundred and eight patients (6 %) with positive LNs were identified. The median number of LNs removed was 17 (IQR 11-24), and median follow-up was 26 months (IQR 14-43). Ninety-one (84 %) patients did not receive adjuvant ADT of whom 60 % had BCR with a median time to recurrence of 8 months. The 1- and 3-year BCR-free probability was 42 and 28 %, respectively. Patients with ≤2 LN+ had significantly better biochemical-free estimated probability compared to those with >2 LN+ (p = 0.002). The total number of LN+ (HR = 1.1; 95 % CI 1.01-1.2, p = 0.04) and Gleason 8-10 (HR = 1.96; 95 % CI 1.1-3.4, p = 0.02) were predictors of BCR on multivariate analysis. CONCLUSION: Among men with positive lymph nodes at time of robotic prostatectomy, those with two or fewer positive nodes and Gleason <8 exhibited favorable biochemical-free survival without adjuvant therapy.
PURPOSE: Limited data are available regarding the oncologic efficacy of pelvic lymph node dissection (PLND) performed during robotic-assisted laparoscopic prostatectomy (RALP) for prostate cancer. We aimed to determine the frequency of pelvic lymph node metastasis and oncological outcomes following RALP with PLND in patients who did not receive adjuvant androgen deprivation therapy (ADT). METHODS: We retrospectively reviewed the records of 1740 consecutive patients who underwent RALP and extended PLND. The primary endpoint was biochemical recurrence (BCR). The estimated BCR probability was obtained using the Kaplan-Meier method. Cox proportional hazard regression models were used to assess for predictors of BCR. RESULTS: One hundred and eight patients (6 %) with positive LNs were identified. The median number of LNs removed was 17 (IQR 11-24), and median follow-up was 26 months (IQR 14-43). Ninety-one (84 %) patients did not receive adjuvant ADT of whom 60 % had BCR with a median time to recurrence of 8 months. The 1- and 3-year BCR-free probability was 42 and 28 %, respectively. Patients with ≤2 LN+ had significantly better biochemical-free estimated probability compared to those with >2 LN+ (p = 0.002). The total number of LN+ (HR = 1.1; 95 % CI 1.01-1.2, p = 0.04) and Gleason 8-10 (HR = 1.96; 95 % CI 1.1-3.4, p = 0.02) were predictors of BCR on multivariate analysis. CONCLUSION: Among men with positive lymph nodes at time of robotic prostatectomy, those with two or fewer positive nodes and Gleason <8 exhibited favorable biochemical-free survival without adjuvant therapy.
Authors: Daniel M Berney; Thomas M Wheeler; David J Grignon; Jonathan I Epstein; David F Griffiths; Peter A Humphrey; Theo van der Kwast; Rodolfo Montironi; Brett Delahunt; Lars Egevad; John R Srigley Journal: Mod Pathol Date: 2010-09-03 Impact factor: 7.842
Authors: Edward M Messing; Judith Manola; Jorge Yao; Maureen Kiernan; David Crawford; George Wilding; P Anthony di'SantAgnese; Donald Trump Journal: Lancet Oncol Date: 2006-06 Impact factor: 41.316
Authors: Christian von Bodman; Guilherme Godoy; Daher C Chade; Angel Cronin; Laura J Tafe; Samson W Fine; Vincent Laudone; Peter T Scardino; James A Eastham Journal: J Urol Date: 2010-05-15 Impact factor: 7.450
Authors: Jonathan L Silberstein; Andrew J Vickers; Nicholas E Power; Raul O Parra; Jonathan A Coleman; Rodrigo Pinochet; Karim A Touijer; Peter T Scardino; James A Eastham; Vincent P Laudone Journal: J Endourol Date: 2011-11-08 Impact factor: 2.942
Authors: Andrew H Feifer; Elena B Elkin; William T Lowrance; Brian Denton; Lindsay Jacks; David S Yee; Jonathan A Coleman; Vincent P Laudone; Peter T Scardino; James A Eastham Journal: Cancer Date: 2011-03-15 Impact factor: 6.860
Authors: Guilherme Godoy; Christian von Bodman; Daher C Chade; Ozdal Dillioglugil; James A Eastham; Samson W Fine; Peter T Scardino; Vincent P Laudone Journal: J Urol Date: 2012-04-11 Impact factor: 7.450
Authors: Alberto Briganti; Michael L Blute; James H Eastham; Markus Graefen; Axel Heidenreich; Jeffrey R Karnes; Francesco Montorsi; Urs E Studer Journal: Eur Urol Date: 2009-03-10 Impact factor: 20.096
Authors: Kevin C Zorn; Mark H Katz; Andrew Bernstein; Sergey A Shikanov; Charles B Brendler; Gregory P Zagaja; Arieh L Shalhav Journal: Urology Date: 2009-06-10 Impact factor: 2.649
Authors: Michael A Liss; Kerrin Palazzi; Sean P Stroup; Ramzi Jabaji; Omer A Raheem; Christopher J Kane Journal: World J Urol Date: 2013-03-20 Impact factor: 4.226
Authors: Georgios Hatzichristodoulou; Stefan Wagenpfeil; Gudrun Wagenpfeil; Tobias Maurer; Thomas Horn; Kathleen Herkommer; Marie Hegemann; Jürgen E Gschwend; Hubert Kübler Journal: World J Urol Date: 2015-09-29 Impact factor: 4.226
Authors: Harriet C Thoeny; Sebastiano Barbieri; Johannes M Froehlich; Baris Turkbey; Peter L Choyke Journal: Radiology Date: 2017-12 Impact factor: 11.105